UCSD registers Phase 2 study of low-dose dexamethasone to prevent Immunocore's tebentafusp CRS
A new trial listed September 3 will test whether steroid premedication can reduce cytokine release syndrome in uveal melanoma patients on tebentafusp.
The only new item this week is a single trial registration tied to Immunocore's tebentafusp.
- "Low-Dose Dexamethasone Premedication for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp in Advanced Uveal Melanoma" (NCT07803562, acronym LODEXA) was listed as not yet recruiting. The study is a single-arm multi-site phase II study of prophylactic low-dose dexamethasone premedication in patients receiving tebentafusp per standard of care for HLA-A*02:01-positive advanced uveal melanoma1, sponsored by the University of California, San Diego with Immunocore Ltd as collaborator, though the registry currently lists only one site, at UC San Diego. The trial plans to enroll 34 participants and its primary outcome is the proportion of participants with grade ≥2 cytokine release syndrome during the first 4 doses of tebentafusp treatment.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.